What is Shanghai Junshi Biosciences Co Days Payable?
Shanghai Junshi Biosciences CoSHJBF +11.67%66 Days Payable is 514.48 as of Dec. 2025, which is 154% above its 10-year median of 202.48. GuruFocus rates SHJBF with a GF Score™ of 66/100 and a GF Value™ of $5.63 (Significantly Undervalued). The stock has 5 warning signs investors should review. Among 703 Biotechnology companies, Shanghai Junshi Biosciences Co ranks better than 76.24% on this metric.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHJBF vs VRTX, REGN, ALNY: Days Payable Comparison
For the Biotechnology subindustry, Shanghai Junshi Biosciences Co's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shanghai Junshi Biosciences Co Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Shanghai Junshi Biosciences Co's Days Payable distribution charts can be found below:
* The bar in red indicates where Shanghai Junshi Biosciences Co's Days Payable falls into.
Shanghai Junshi Biosciences Co Days Payable Calculation
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai Junshi Biosciences Co (SHJBF) has a Days Payable of 514.48 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Shanghai Junshi Biosciences Co and its competitors. This is 154% above median its historical median of 202.48. Over the past decade, Shanghai Junshi Biosciences Co's Days Payable has ranged from 41.20 to 39,126.67. According to the industry distribution chart, Shanghai Junshi Biosciences Co ranks #167 out of 703 companies in the Biotechnology industry, placing it in the top 23.8%.
Is Shanghai Junshi Biosciences Co's Days Payable too high?
Shanghai Junshi Biosciences Co's current Days Payable of 514.48 is 154% above median its 10-year median of 202.48. Over the past 10 years, this metric has ranged from a low of 41.20 to a high of 39,126.67. The Biotechnology industry median Days Payable is 113.76. Shanghai Junshi Biosciences Co's value of 514.48 is 352.3% above this industry median. Based on the distribution chart, Shanghai Junshi Biosciences Co ranks #167 out of 703 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Shanghai Junshi Biosciences Co has a GF Score™ of 66/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Shanghai Junshi Biosciences Co's Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Shanghai Junshi Biosciences Co ranks #167 out of 703 companies for Days Payable. This places Shanghai Junshi Biosciences Co in the top 24% of its industry — outperforming the majority of peers. The industry median Days Payable is 113.76. Shanghai Junshi Biosciences Co's value of 514.48 is 352.3% above this benchmark. Historically, Shanghai Junshi Biosciences Co's own Days Payable has ranged from 41.20 to 39,126.67 over the past decade. While the company's 10-year median is 202.48 vs. the industry median of 113.76, Shanghai Junshi Biosciences Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.76, based on 703 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shanghai Junshi Biosciences Co's current Days Payable of 514.48 is 352.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Shanghai Junshi Biosciences Co and its competitors. For the Biotechnology industry, the median Days Payable is 113.76 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shanghai Junshi Biosciences Co's current Days Payable is 514.48, which is 154% above median its own 10-year median of 202.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai Junshi Biosciences Co stock overvalued right now?
Based on GuruFocus' analysis, Shanghai Junshi Biosciences Co (SHJBF) is currently considered Significantly Undervalued. The stock's GF Value™ is $5.63, compared to a current price of $3.35 — trading 40.5% below its estimated fair value. The current Days Payable is 514.48, which is 154% above median its 10-year median of 202.48 and 352.3% above the Biotechnology industry median of 113.76. Shanghai Junshi Biosciences Co's overall GF Score™ is 66/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Shanghai Junshi Biosciences Co (SHJBF), the current Days Payable is 514.48 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shanghai Junshi Biosciences Co (SHJBF) Overvalued in 2026?
Based on GuruFocus' analysis, Shanghai Junshi Biosciences Co stock appears to be undervalued.
The current stock price of $3.35 is trading 40.5% below its estimated GF Value™ of $5.63.
GuruFocus considers Shanghai Junshi Biosciences Co to be Significantly Undervalued.
Key valuation signals for SHJBF:
Days Payable: 514.48 (154% above median its 10-year median of 202.48)
GF Value™: $5.63 vs. price of $3.35 (40.5% below fair value)
Industry Position: 352.3% above the Biotechnology median (#167 of 703)
No single metric tells the full story. See the SHJBF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shanghai Junshi Biosciences Co Business Description
Shanghai Junshi Biosciences Co Ltd is mainly involved in the discovery, development, and commercialisation of therapeutic drugs. It focuses on the development and commercialization of several kinds of drugs, ranging from monoclonal antibodies to various drug modalities, including small molecules, ADCs, bi-specific or multi-specific antibodies, fusion proteins, nucleic acid drugs, and vaccines, as well as the exploration of next-generation therapies, including those for cancer and autoimmune diseases. The Group's portfolio includes commercialized drugs such as Tuoyi, Junmaikang, Mindewei, and Junshida, as well as products in clinical studies or in the marketing application stage. Geographically, it derives maximum revenue from Mainland China, and the rest from USA, India, and other markets.
66GF Score
Get the complete analysis for SHJBF
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHJBF has been successfully added to your 
